Long-term spontaneous regression of Stage IV diffuse large B-cell lymphoma

Yoshiki Furukawa; Jun Ando; Miki Ando; Shintaro Kinoshita; Yoko Edahiro; Takuya Furuta; Koichi Ohshima; Norio Komatsu

doi:10.3960/jslrt.21002

Case report

Long-term spontaneous regression of Stage IV diffuse large B-cell lymphoma

Yoshiki Furukawa, Jun Ando, Miki Ando , Shintaro Kinoshita, Yoko Edahiro, Takuya Furuta, Koichi Ohshima, Norio Komatsu

Author information

Yoshiki Furukawa
Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan,
Jun Ando
Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan,
Miki Ando Corresponding author
Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan,
Division of Stem Cell Therapy, Distinguished Professor Unit, The Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo, Japan,
Shintaro Kinoshita
Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan,
Yoko Edahiro
Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan,
Takuya Furuta
Department of Pathology, School of Medicine, Kurume University, Asahimachi 67, Kurume City, Fukuoka, Japan
Koichi Ohshima
Department of Pathology, School of Medicine, Kurume University, Asahimachi 67, Kurume City, Fukuoka, Japan
Norio Komatsu
Department of Hematology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, Japan,

Keywords: Spontaneous regression, diffuse large B-cell lymphoma, long-term remission

JOURNAL OPEN ACCESS

2021 Volume 61 Issue 3 Pages 168-172

DOI https://doi.org/10.3960/jslrt.21002

Browse “Advance online publication” version

Details

Abstract

Diffuse large B cell lymphoma (DLBCL) is an aggressive disorder accounting for >30% of all lymphomas. Its prognosis is poor due to a high relapse rate. Spontaneous regression (SR) in DLBCL is rare, with only a few reported cases. Moreover, almost all of these were low-grade lymphomas with an average SR duration of 13 mo. As the cause of SR is unknown, there are many theories such as trauma, infection, medication, and an antitumor immune response. We present a patient with progressive DLBCL who demonstrated SR for >42 mo. Although treatment for lymphoma usually starts soon after diagnosis, insights into SR of lymphomas may lead to new treatment strategies.

Corresponding author

Register with J-STAGE for free!